After decades of decline, rates of cervical cancer within Canada have plateaued, according to the Canadian Cancer Society — a ...
Maina Modu, an immunization officer in Nigeria’s northeastern Borno state, lost his wife, Hauwa, to cervical cancer in 2011.
Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced that Palmetto GBA, the Medicare Administrative Contractor that administers the Molecular ...
Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.
PDS Biotechnology Corporation (NASDAQ: PDSB) Q3 2025 Earnings Call Transcript November 13, 2025 ...
Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsJay Short - Co-Founder, CEO & ChairmanSheri Lydick - ...
FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...
Link to the article in Clinical Cancer Research.] The study utilized Droplet's LymphDetect (TM) liquid biopsy assay for HPV-independent head & neck cancer. Results from two cohorts (initial n = 36, ...
PDS Biotechnology Corp (PDSB) reports promising trial results and strategic collaborations, despite financial hurdles and trial amendments.
4d
PDS Biotech outlines trial protocol amendment for accelerated PFS endpoint in HPV16-positive cancer
Get key insights from PDS Biotech’s Q3 2025 earnings call, including regulatory updates for PDS0101 in HPV16+ cancer and financial highlights.
Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck ...
The Head and Neck Cancer Drugs/Therapeutics Market is experiencing substantial growth, valued at USD 4.2 Billion in 2024 and projected to reach USD 8.5 Billion by 2033. This expansion reflects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback